Drugs / AZD1386
last change Jan 2013 re-read 2 minutes ago

AZD1386

Small molecule targets TRPV1 via inhibition

Developed for
chronic pain syndrome · esophageal disorder · neuropathy, painful
Investigated by
AstraZeneca

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT00945178 Aug → Sep 2009 AstraZeneca Terminated No outcome recorded
Phase 1 NCT00832169 Jan → Feb 2009 AstraZeneca Completed No outcome recorded
Phase 1 NCT00736658 Jun → Sep 2008 chronic pain syndrome AstraZeneca Completed No outcome recorded
Phase 1 NCT00711048 Jun 2008 → Jul 2009 AstraZeneca Completed No outcome recorded
Phase 1 NCT00714337 Jun → Aug 2008 AstraZeneca Completed No outcome recorded
Phase 1 NCT00690079 Feb → Oct 2008 chronic pain syndrome AstraZeneca Completed No outcome recorded
Phase 1 NCT00692146 Jan → May 2008 AstraZeneca Completed No outcome recorded
Phase 24 trials
Phase 2 NCT01019928 Nov 2009 → Jan 2011 esophageal disorder AstraZeneca Completed No outcome recorded
Phase 2 NCT00976534 Sep 2009 → Feb 2010 neuropathy, painful AstraZeneca Terminated No outcome recorded
Phase 2 NCT00878501 Mar → Jul 2009 AstraZeneca Terminated No outcome recorded
Phase 2 NCT00672646 Apr → Jun 2008 AstraZeneca Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as AZD1386 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00878501
10

NCT00976534

NCT00711048

NCT00714337

NCT00832169

NCT00690079

NCT00736658

NCT00945178

NCT00692146

NCT01019928

NCT00672646

Action Inhibit “AIM: To investigate the effect of a TRPV1 antagonist (AZD1386) on experimentally induced oesophageal pain.” PMID 21410733 Mar 2011
Modality Small molecule CHEMBL3545039
Route Oral “95mg, oral solution, single dose” NCT00672646
Target TRPV1 TRPV1 antagonist AZD1386” PMID 23320520 Jan 2013